- Home
- ABEO vs LUNG Comparison
ABEO vs LUNG Comparison
Compare ABEO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- LUNG
- Stock Information
- Founded
- ABEO N/A
- LUNG 1995
- Country
- ABEO United States
- LUNG United States
- Employees
- ABEO N/A
- LUNG N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- ABEO Health Care
- LUNG Health Care
- Exchange
- ABEO Nasdaq
- LUNG Nasdaq
- Market Cap
- ABEO 243.9M
- LUNG 256.3M
- IPO Year
- ABEO 1980
- LUNG 2020
- Fundamental
- Price
- ABEO $5.19
- LUNG $6.19
- Analyst Decision
- ABEO Strong Buy
- LUNG Buy
- Analyst Count
- ABEO 3
- LUNG 6
- Target Price
- ABEO $18.00
- LUNG $11.92
- AVG Volume (30 Days)
- ABEO 251.8K
- LUNG 214.3K
- Earning Date
- ABEO 11-14-2024
- LUNG 02-19-2025
- Dividend Yield
- ABEO N/A
- LUNG N/A
- EPS Growth
- ABEO N/A
- LUNG N/A
- EPS
- ABEO N/A
- LUNG N/A
- Revenue
- ABEO N/A
- LUNG $79,302,000.00
- Revenue This Year
- ABEO N/A
- LUNG $22.26
- Revenue Next Year
- ABEO $15,721.96
- LUNG $18.72
- P/E Ratio
- ABEO N/A
- LUNG N/A
- Revenue Growth
- ABEO 147.52
- LUNG 22.34
- 52 Week Low
- ABEO $3.05
- LUNG $5.46
- 52 Week High
- ABEO $9.01
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- ABEO 34.35
- LUNG 42.79
- Support Level
- ABEO $5.05
- LUNG $6.24
- Resistance Level
- ABEO $5.66
- LUNG $7.27
- Average True Range (ATR)
- ABEO 0.27
- LUNG 0.39
- MACD
- ABEO -0.06
- LUNG -0.04
- Stochastic Oscillator
- ABEO 13.21
- LUNG 6.09
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.